Considerations for the New Four-Month Rifapentine-Moxifloxacin Regimen for Drug-Susceptible TB in the U.S.

Lisa Armitige, MD | David Ashkin, MD | Richard Chaisson, MD | Lisa Chen, MD | Susan Dorman, MD | Ekaterina Kurbatova, MD, PhD | Alfred Lardizabal, MD | Payam Nahid, MD | Patrick Phillips, PhD

Moderator: Neela Goswami, MD